Acurx Pharmaceuticals Reports Significant Reduction in Operating Expenses and Net Losses for Q2 2025

Acurx Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, revealing a significant reduction in both operating expenses and net losses compared to the same period in 2024. The company recorded total operating expenses of $2.27 million for the three months ended June 30, 2025, a decrease of 45% from $4.12 million in the prior year. This decline was primarily driven by a 71% reduction in research and development expenses, which fell to $524,210 from $1.83 million, and a 24% decrease in general and administrative expenses, which totaled $1.75 million compared to $2.30 million in the previous year. The net loss for the quarter was $2.25 million, down 46% from $4.12 million in the same quarter of 2024.

For the first half of 2025, Acurx reported total operating expenses of $4.45 million, a 48% decrease from $8.50 million in the first half of 2024. The net loss for this period was $4.40 million, compared to $8.50 million in the prior year, reflecting a substantial improvement in financial performance. The company attributed these changes to lower manufacturing and consulting costs, as well as reduced share-based compensation expenses.

In terms of liquidity, Acurx's cash position improved significantly, with cash and cash equivalents totaling approximately $6.06 million as of June 30, 2025, up from $3.71 million at the end of 2024. The company has funded its operations primarily through equity financing, raising approximately $12.9 million from various offerings since its inception. Notably, Acurx entered into an equity line of credit purchase agreement with Lincoln Park Capital Fund, allowing for the potential sale of up to $12 million in shares, of which $0.6 million has been raised to date.

Strategically, Acurx is focused on advancing its lead antibiotic candidate, ibezapolstat, which targets Clostridioides difficile infections. The company is in the late stages of clinical development and is exploring partnerships for commercialization. Acurx has also implemented a 1-for-20 reverse stock split effective August 4, 2025, to comply with Nasdaq listing requirements, as the company had previously received notices regarding non-compliance with minimum stockholders' equity and bid price requirements.

Looking ahead, Acurx anticipates continued operational losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company remains committed to exploring additional financing options to support its research and development activities, although it acknowledges the inherent uncertainties and risks associated with the biopharmaceutical industry.